VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Slides:

Advertisements

Similar presentations

Venous thromboembolism: how long to treat?

Advertisements

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,

Addressing the Challenges in Primary and Secondary Stroke Prevention

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

NOACs for Cancer-Associated Thrombosis:

NOACs In Long-term VTE Treatment: A State Of The Art Review

Long-Term Treatment of VTE: Case Studies

Cardiogenic Shock.

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

NOACs in Clinical Practice: Are They All the Same?

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

A Case Challenge: Anticoagulant Choices for Acute PE

Antiplatelet Therapy and Secondary Prevention

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Treatment Options to Consider

New Oral Anticoagulants and VTE Management

Real-World Safety of NOACs: What Do We Know Today?

VTE Treatment Conventional Approach

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Real-World Evidence in VTE

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

Factor Xa Inhibitors in PAD

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

At the Crossroads of Coagulation

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

VTE Treatment and Secondary Prevention

VTE Treatment Trials Initial Dosing

Duration of Therapy

Treatment of DVT VKA vs VKA + Heparin

ACCP Guidelines Treatment of Acute PE

ESC Guidelines Treatment of Acute PE

VTE Treatment Trials Single-Drug Approach vs Upfront Heparin

VTE Treatment Trials Efficacy and Safety Outcomes

AMPLIFYa Study Design

PADIS-PE

VTE Treatment Trials Duration of Therapy

Recurrence Risk After Limited Duration of Anticoagulant Treatment for Late Second VTE

CATCH

VTE Extension Trials Efficacy and Safety Outcomes

VTE Treatment NOACs

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)